查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2151566

雙相情感障礙市場規模、佔有率和趨勢分析報告：按類型、藥物類別、分銷管道、地區和細分市場預測（2026-2033 年）

Bipolar Disorder Market Size, Share & Trends Analysis Report By Type, By Drug Class, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

全球雙極性情感障礙市場預計到 2025 年將達到 51 億美元，到 2026 年將成長到 53 億美元，到 2033 年將達到 64 億美元，2026 年至 2033 年的複合年成長率為 2.7%。

北美是推動市場成長的主要力量，預計到2025年將佔全球銷售額的40.0%。這一市場成長的主要驅動力是雙相情感障礙盛行率的上升，以及政府加強投入以支持提高公眾意識的宣傳活動和促進醫療保健及研究機構的發展。此外，快速的都市化和生活方式的改變導致壓力和藥物濫用問題日益嚴重，也加劇了雙極性情感障礙的發生率。因此，對有效診斷、治療和長期管理的需求不斷成長，進一步推動了市場成長。

雙極性情感障礙可能由多種遺傳和環境因素誘發，包括壓力性生活事件、創傷或情緒虐待。由於生活方式的改變和職場環境壓力的增加，雙相情感障礙的診斷率正在上升。此外，政府和非政府組織主導的各項措施提高了公眾對雙相情感障礙的認知，促使更多人尋求醫療協助以診斷和治療精神疾病。這些努力也有助於轉變人們對雙相情感障礙的認知，減少社會歧視，從而進一步推動了該市場的成長。

此外，大型醫療機構對雙極性情感障礙及其治療相關研發的大量投入也促進了市場成長。因此，可用於治療躁鬱症的藥物種類不斷增加。隨著人們對雙極性情感障礙的認知不斷提高，對診斷和治療的需求也在成長。在雙極性情感障礙相關藥物消費量不斷增加的情況下，各公司正透過獲得監管部門的批准，不斷增加推向市場的藥物種類。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章：雙極性情感障礙市場：變數、趨勢與範圍

  • 市場概況及未來展望
  • 市場規模和成長前景
  • 市場動態
  • 雙極性情感障礙市場分析工具

第4章：雙極性情感障礙市場：按類型分類的估算與趨勢分析

  • 雙極性情感障礙市場：按類型分類的趨勢分析，2025 年和 2033 年
  • 情緒穩定劑
  • 抗驚厥藥物
  • 抗精神病藥物
  • 抗憂鬱症
  • 抗焦慮藥物
  • 其他類型

第5章：雙極性情感疾患市場：依藥物類別分類的估計與趨勢分析

  • 雙極性情感障礙市場：基於藥物類別的趨勢分析，2025 年和 2033 年
  • 選擇性血清素再回收抑制劑
  • 正腎上腺素再回收抑制劑
  • 三環抗憂鬱藥物
  • 單胺氧化酵素抑制劑
  • 苯二氮平類藥物
  • BETA受體阻斷劑
  • 其他藥物分類

第6章：雙極性情感障礙市場：按分銷管道分類的估算與趨勢分析

  • 雙極性情感障礙市場：按分銷管道分類的趨勢分析（2025 年和 2033 年）
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第7章：雙極性情感障礙市場：區域估算與趨勢分析

  • 雙相情感障礙市場區域佔有率，2025 年和 2033 年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第8章 競爭情勢

  • 主要市場參與企業的最新趨勢及影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Advanced Micro Devices
    • AstraZeneca
    • Eli Lilly and Company
    • GSK plc
    • Johnson & Johnson Services, Inc
    • Pfizer Inc.
    • AbbVie Inc.
    • Otsuka Holdings Co., Ltd.
    • Bristol-Myers Squibb Company
    • Teva Pharmaceutical Industries Ltd.
    • Sumitomo Pharma America, Inc
簡介目錄
Product Code: GVR-2-68038-033-0

The global bipolar disorder market was valued at USD 5.1 billion in 2025 and is projected to grow from USD 5.3 billion in 2026 to USD 6.4 billion in 2033, at a CAGR of 2.7% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 40.0% in 2025. The growth of this market is primarily driven by the increasing prevalence of bipolar disorder and rising government investments to enhance awareness and support advancements in healthcare and research institutions. Furthermore, rapid urbanization and evolving lifestyles have contributed to higher levels of stress and substance abuse, leading to a growing incidence of bipolar disorder. Consequently, the need for effective diagnosis, treatment, and long-term management is driving the market growth.

Bipolar disorder can occur due to various genetic and environmental factors, such as stressful life events, trauma, or emotional abuse, which can lead to the triggering of the condition. Due to changing lifestyles and an increase in stressful work environments, there is a rise in the diagnosis of bipolar disorders. Furthermore, increased awareness of bipolar disorders due to initiatives led by governments and NGOs has increased the number of patients seeking medical help to diagnose and treat their mental health. These initiatives have resulted in a change of perspective and the elimination of stigma related to bipolar disorders, which has further helped in the growth of this market.

Furthermore, substantial investments by leading medical institutes in research and development for bipolar disorder and its treatment have contributed to market growth. Therefore, there is an increase in the number of medicines available to treat bipolar disorders. Due to increased awareness, there is a rise in demand for diagnosis and medication for bipolar disorders. With the increase in the consumption of medicines related to bipolar disorders, companies are increasing the number of drugs in the market by getting approvals from regulatory bodies.

Global Bipolar Disorder Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities across each sub-segment from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global bipolar disorder market report based on type, drug class, distribution channel, and region:

  • Type Outlook (Revenue, USD Billion, 2021 - 2033)

Mood stabilizer

Anticonvulsants

Antipsychotic drugs

Antidepressant drugs

Antianxiety drugs

Other Types

  • Drug Class Outlook (Revenue, USD Billion, 2021 - 2033)

Selective serotonin reuptake inhibitor

Serotonin norepinephrine reuptake inhibitor

Tricyclic antidepressant drugs

Monoamine oxidase inhibitors

Benzodiazepines

Beta blockers

Other Drug Classes

  • Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

  • Regional Outlook (Revenue, USD Billion, 2021 - 2033)

North America

    • U.S.
    • Canada
    • Mexico

Europe

    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway

Asia Pacific

    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand

Latin America

    • Brazil
    • Argentina

Middle East and Africa (MEA)

    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Bipolar Disorder Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Bipolar Disorder Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Bipolar Disorder Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Bipolar Disorder Market: Type Movement Analysis, 2025 & 2033 (USD Million)
  • 4.3. Mood Stabilizer
    • 4.3.1. Mood Stabilizer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Anticonvulsants
    • 4.4.1. Anticonvulsant Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Antipsychotic Drugs
    • 4.5.1. Antipsychotic Drugs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Antidepressant Drugs
    • 4.6.1. Antidepressant Drugs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Antianxiety Drugs
    • 4.7.1. Antianxiety Drugs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.8. Other Types
    • 4.8.1. Other Types Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Bipolar Disorder Market: Drug Class Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Bipolar Disorder Market: Drug Class Movement Analysis, 2025 & 2033 (USD Million)
  • 5.3. Selective Serotonin Reuptake Inhibitor
    • 5.3.1. Selective Serotonin Reuptake Inhibitor Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Serotonin Norepinephrine Reuptake Inhibitor
    • 5.4.1. Serotonin Norepinephrine Reuptake Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Tricyclic Antidepressant Drugs
    • 5.5.1. Tricyclic Antidepressant Drugs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Monoamine Oxidase Inhibitors
    • 5.6.1. Monoamine Oxidase Inhibitors Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Benzodiazepines
    • 5.7.1. Benzodiazepines Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.8. Beta Blockers
    • 5.8.1. Beta Blockers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.9. Other Drugs Classes
    • 5.9.1. Other Drugs Classes Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Bipolar Disorder Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Bipolar Disorder Market: Distribution Channel Movement Analysis, 2025 & 2033 (USD Million)
  • 6.3. Hospital Pharmacies
    • 6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Online Pharmacies
    • 6.5.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Bipolar Disorder Market: Regional Estimates & Trend Analysis

  • 7.1. Bipolar Disorder Market Share, By Region, 2025 & 2033, USD Million
  • 7.2. North America
    • 7.2.1. North America Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. China Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Australia Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.6. South Korea
      • 7.4.6.1. South Korea Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Advanced Micro Devices
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. AstraZeneca
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Eli Lilly and Company
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. GSK plc
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Johnson & Johnson Services, Inc
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Pfizer Inc.
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. AbbVie Inc.
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Otsuka Holdings Co., Ltd.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Bristol-Myers Squibb Company
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Teva Pharmaceutical Industries Ltd.
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives
    • 8.4.11. Sumitomo Pharma America, Inc
      • 8.4.11.1. Participant's Overview
      • 8.4.11.2. Financial Performance
      • 8.4.11.3. Product Benchmarking
      • 8.4.11.4. Recent Developments/ Strategic Initiatives